Scarica l'app Stockscreener
0.391
9.43%
-0.0407
Dopo l'orario di chiusura:
.40
0.009
+2.30%
Precedente Chiudi:
$0.4317
Aprire:
$0.4153
Volume 24 ore:
117.95K
Relative Volume:
0.49
Capitalizzazione di mercato:
$26.28M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-0.3342
EPS:
-1.17
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
-7.52%
1M Prestazione:
+32.54%
6M Prestazione:
-48.48%
1 anno Prestazione:
-63.46%
Intervallo 1D:
$0.385
$0.4439
Intervallo di 1 settimana:
$0.385
$0.48
Portata 52W:
$0.257
$1.33
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Confronta PASG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.391 | 26.28M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
| 2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Downgrade | Goldman | Buy → Neutral |
| 2021-07-01 | Iniziato | Raymond James | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-02-04 | Iniziato | Guggenheim | Buy |
| 2021-01-25 | Iniziato | Wedbush | Outperform |
| 2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2020-03-24 | Iniziato | Cowen | Outperform |
| 2020-03-24 | Iniziato | Goldman | Buy |
| 2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
Passage Bio, Inc. (NASDAQ:PASG) Stake Cut by Two Sigma Investments LP - Defense World
Two Sigma Investments LP Makes New Investment in BioVie Inc. (NASDAQ:BIVI) - Defense World
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
American Battery Technology (NASDAQ:ABAT) Shares Purchased by Two Sigma Investments LP - Defense World
Millennium Management LLC Purchases Shares of 37,704 Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Squarepoint Ops LLC Has $36,000 Stake in Passage Bio, Inc. (NASDAQ:PASG) - Defense World
Semrush Holdings, Inc. (NASDAQ:SEMR) Shares Purchased by Bank of America Corp DE - Defense World
Lumina Gold (OTCMKTS:LMGDF) Trading Down 0.3% – Here’s Why - Defense World
Obsidian Energy (OTCMKTS:OBELF) Shares Up 2.7% – Here’s Why - Defense World
Carbios SAS (OTCMKTS:COOSF) Stock Price Up 5% – Here’s Why - Defense World
Suncrest Bank (OTCMKTS:SBKK) Shares Up 1% – Should You Buy? - Defense World
Color Star Technology (NASDAQ:CSCW) Trading 0.5% Higher – Here’s What Happened - Defense World
Inventiva (NASDAQ:IVA) Stock Price Up 0.8% – Here’s Why - Defense World
Eaton Vance Enhanced Equity Income Fund (NYSE:EOI) Shares Up 0.1% – Time to Buy? - Defense World
Nano Magic (OTCMKTS:NMGX) Shares Up 5% – What’s Next? - Defense World
Jane Street Group LLC Grows Holdings in Passage Bio, Inc. (NASDAQ:PASG) - Defense World
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Passage Bio, Inc. (NASDAQ:PASG) Shares Purchased by Northern Trust Corp - Defense World
Passage Bio Adopts Key Proposals at Annual Meeting - TipRanks
D. E. Shaw & Co. Inc. Increases Holdings in 908 Devices Inc. (NASDAQ:MASS) - Defense World
VintaBio Showcases Breakthrough Gene Therapy Manufacturing Platform - MyChesCo
Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Guggenheim Adjusts Price Target for Passage Bio (PASG) | PASG St - GuruFocus
Cubist Systematic Strategies LLC Grows Holdings in Intevac, Inc. (NASDAQ:IVAC) - Defense World
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MyChesCo
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development - MSN
Wedbush Issues Pessimistic Estimate for Passage Bio Earnings - Defense World
Gm1 Gangliosidosis Treatment Market in 2025 Detailed Study - openPR.com
Dimensional Fund Advisors LP Has $1.14 Million Stock Holdings in Traeger, Inc. (NYSE:COOK) - Defense World
TransAct Technologies Incorporated (NASDAQ:TACT) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Tower Research Capital LLC TRC - Defense World
Tower Research Capital LLC TRC Acquires 7,927 Shares of The E.W. Scripps Company (NASDAQ:SSP) - Defense World
Braskem Marks 15 Years of I’m green Bio-Based Portfolio with Expanded Production - MyChesCo
Passage Bio Reports Q1 2025 Financial Results - TipRanks
Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating - marketscreener.com
Passage Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Passage Bio Q1 Income From Operations USD -16.459 Million - marketscreener.com
Passage Bio (PASG) Advances Phase 1/2 Trial for PBFT02, Eyes Fut - GuruFocus
Passage BIO, Inc. SEC 10-Q Report - TradingView
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - The Manila Times
Passage Bio (PASG) Expected to Announce Earnings on Tuesday - Defense World
2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked - BioSpace
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MyChesCo
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus
Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia
Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Passage Bio Inc Azioni (PASG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 22 '25 |
Sale |
0.34 |
78,049 |
26,537 |
6,807,523 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 24 '25 |
Sale |
0.32 |
68,195 |
21,822 |
6,650,000 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 17 '25 |
Sale |
0.33 |
77,090 |
25,440 |
6,885,572 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 16 '25 |
Sale |
0.33 |
61,638 |
20,341 |
6,962,662 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 15 '25 |
Sale |
0.38 |
10,326 |
3,924 |
7,024,300 |
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):